Successful treatment of gynecologic malignancy with trastuzumab deruxtecan in three patients with HER2 mutations
These cases illustrate the potential for trastuzumab deruxtecan to be useful among a broader range of patients than current guidelines include and suggest that comprehensive genomic testing is necessary to help identify patients whose disease may be susceptible to HER2-targeted therapies.
Authors
- Josephine S. Kim
- Shayan Rayani
- Nita K. Lee (ORCID: https://orcid.org/0000-0002-7384-9975)
- Gini F. Fleming (ORCID: https://orcid.org/0000-0003-2845-4023)
- Christopher M. Straus (ORCID: https://orcid.org/0000-0002-4418-1304)
- Anusha Vemuri
- Katherine C. Kurnit (ORCID: https://orcid.org/0000-0003-3205-0128)
- Julieta E. Barroeta (ORCID: https://orcid.org/0000-0002-6632-9285)
- S. Diane Yamada (ORCID: https://orcid.org/0000-0001-7922-4784)
- Divya Choudhury
Institutions
- University of Chicago (US)
- University of Chicago Medical Center (US)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1016/j.gore.2025.101974
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05